The company
Colgate-Palmolive Company
CL · NYSE
CL stood above a rising 150-day average in 27 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 5.2% above that average now. Household & Personal Care: 24% of its 21 stocks in an uptrend (±0 points in four weeks); Consumer Staples: 23% (+1 points in four weeks).
Statistics
- Rotation
- Above a falling average
- Weeks in an uptrend
- out for 8
- Industry in uptrend
- 24% 0 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $114.1M
- Officials’ trades on record
- 128
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.
Household & Personal Care: A minority of its stocks are in an uptrend and the share has held steady. Consumer Staples: A minority of its stocks are in an uptrend and the share has held steady.
Money in and out
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
128 disclosed lines: House 103, Senate 12, executive 13; 36 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Kevin Hern House: U.S. House ClerkOK01 | soldjoint | $1k–$15k | 2 Sep 2026filed 25 Sep 2026 |
| Kevin Hern House: U.S. House ClerkOK01 | sold | $1k–$15k | 31 Aug 2026filed 25 Sep 2026 |
| Kevin Hern House: U.S. House ClerkOK01 | sold | $1k–$15k | 27 Aug 2026filed 25 Sep 2026 |
| Kevin Hern House: U.S. House ClerkOK01 | soldjoint | $1k–$15k | 19 Aug 2026filed 1 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $50k–$100k | 12 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $100k–$250k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 28 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $250k–$500k | 17 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 10 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 26 Mar 2026filed 14 May 2026 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Panagiotis TsourapasCOO, CD, EMEA, APac, Skin | sold | 10,000at $92.05 | 24 Aug 2026filed 26 Aug 2026 |
| John T. CahillDirector | sold | 4,170at $93.37 | 6 Aug 2026filed 7 Aug 2026 |
| Noel R. WallaceChairman, President & CEO | sold | 161,021at $92.52 | 5 Aug 2026filed 6 Aug 2026 |
| Noel R. WallaceChairman, President & CEO | sold | 161,021at $91.92 | 4 Aug 2026filed 6 Aug 2026 |
| Gregory MalcolmEVP and Controller | sold | 2,300at $88.44 | 15 May 2026filed 18 May 2026 |
| Sally MasseyChief People Officer | sold | 8,599at $87.41 | 7 May 2026filed 11 May 2026 |
| Panagiotis TsourapasCOO, Eur., APac, Afr Eur, Skin | sold | 15,000at $97.81 | 12 Feb 2026filed 13 Feb 2026 |
| Panagiotis TsourapasCOO, Eur., APac, Afr Eur, Skin | sold | 35,000at $94.61 | 11 Feb 2026filed 13 Feb 2026 |
| John HazlinChief Growth Officer | sold | 20,989at $94.25 | 10 Feb 2026filed 12 Feb 2026 |
| Gregory MalcolmEVP and Controller | sold | 12,747at $94.91 | 6 Feb 2026filed 10 Feb 2026 |
| Sally MasseyChief Human Resources Officer | sold | 15,851at $95.03 | 5 Feb 2026filed 9 Feb 2026 |
| Noel R. WallaceChairman, President & CEO | sold | 45,568at $93.91 | 4 Feb 2026filed 6 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.